There are two main projects in the PharmNovo pipeline:

  • Development of our candidate drug is PN6047, a very selective biased agonists of the delta opioid receptor.
  • Discovery of small peptide CGRP receptor antagonists aimed primarily at migraine therapy.

PN6047 – our lead compound

Our focus is on PN6047, a novel potent and selective, biased delta-opioid receptor agonist, which is predicted to reduce chronic pain and combat other conditions involving sensory hypersensitivity, including chronic cough and itch.

In pre-clinical studies, PN6047 has shown high potency and efficacy in reducing chronic pain without any indications of unwanted morphine-like side effects.

PN6047 has an excellent pre-clinical safety profile and fully medicine-like properties predicting favorable dosing in humans. Its metabolic profile also indicates possibilities for developing combination therapies.

Find us

PharmNovo AB
Medicon Village AB
Scheelevägen 6
SE-223 81 Lund, Sweden